To The Moon

BTCUSD - Monthly Logarithmic Chart This primary trendline has served as a definitive floor for every major correction exceeding 50% since 2014. BTC is currently trading 3.9x ATR% below the 50-MA. This extension suggests an asymmetric risk-reward profile favoring the long side, provided you can entry manage a base or intraday entry on LoD off a key technical level, ie. $59,998 low coinciding with round number support $60,000. Further breakdown from current level will mirror November 2018, the last time BTC hit -4x ATR% from the 50-MA. That instance saw a further -42% flush from a bear flag setup before the ultimate bottom was set, leading to a massive 350% 6-month surge. If the current market correction deepens with more pain displayed on media headlines, BTC is shaping up to be a high-conv

Compelling 5.4% dividend yield, supported by resilient fee-based cash flows. Recent acquisitions of Magellan, EnLink, and Medallion have solidified OKE as a top-tier diversified midstream operator. Approximately 90% of earnings are now fee-based, significantly reducing direct commodity price exposure. Trading at a discount to our intrinsic value estimate, particularly given the synergy potential from recent M&A. Long-term volume risk tied to energy transition pressures on refined products and regulatory hurdles for new infrastructure. Investment Thesis $ONEOK Inc(OKE)$ is a diversified midstream energy leader operating an extensive 60,000-mile pipeline network that connects prolific U.S. supply basins, including the Permian, Williston, and Mid-

$HIMS is shaking up the pharma space, challenging $NVO’s patents in a high-stakes bet that could disrupt the weight loss market. Both $NVO and $LLY face significant downside risk if litigation goes against them, making this a fascinating clash between nimble disruptors and Big Pharma. Meanwhile, $MGM is quietly reducing its float, repurchasing 5.5% of shares in a single quarter, signaling confidence amid broader market volatility. Investors should watch legal battles and corporate capital moves alike for asymmetric opportunities. 1. $Hims & Hers Health Inc.(HIMS)$ My gut feeling is that $HIMS is playing the ultimate disruption card. They’re pushing so hard Novo sues, which ultimately leads to Novo defending — and potentially invalidating — the

Expanding your horizons outside of Mega Cap Growth $Vanguard Mega Cap Growth ETF(MGK)$ $iShares S&P 500 Growth ETF(IVW)$ and Tech $Technology Select Sector SPDR Fund(XLK)$ might feel like unchartered territory for your watchlist, but that’s where the opportunity lies. Stay agile and embrace the market's current rotation. If you keep your screening parameters too rigid and not expand your product selection, you risk sitting on the sidelines during the next big move—just like the rally in metals and miners. Previous sharing on $SPDR S&P Bank ETF(KBE)$ $SPDR S&P Regional Banking